Sep 15, 2025 4:07 PM Eastern Daylight Time Alex M. Azar II Joins Guardant Health Board of Directors Share PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Cente ...

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has reached a strategic agreement with LabFlorida/SunDx Labs to provide residents of senior living communities access to Guardant Shieldâ,,g, the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for colorectal cancer (CRC). As part of the agreement, LabFlorida will serve as the exclusive distributor to senior living c. ...

PresentationKallum TitchmarshEquity Analyst Okay. Great. I think we can get started, everyone. Kallum Titchmarsh here from the Life Sciences team at Morgan Stanley. Really pleased today to be joined by Helmy Eltoukhy, Chairman, Co-Founder and Co-CEO; AmirAli Talasaz, Co-Founder and Co-CEO; and we have Mike Bell, CFO as well with us. So before we get started, I have to read you some disclosures. So please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. So mayb ...

Summary of Guardant Health FY Conference Call (September 08, 2025) Company Overview - **Company**: Guardant Health (NasdaqGS:GH) - **Industry**: Life Sciences, specifically focused on cancer diagnostics and liquid biopsy technology Key Points and Arguments Company Progress and Mission - Guardant Health has evolved significantly since its founding 13 years ago, achieving its goal of offering Medicare-reimbursed products across therapy selection, minimal residual disease (MRD), and screening [2][3] Partnership and Revenue Opportunities - The partnership with Path Group is expected to enhance the accessibility and distribution of the Shield test, potentially making it the largest diagnostic plan outside of COVID testing [5][6] - Path Group is integrated with 250 health systems and serves over 15,000 physicians, testing over 5 million patients [6] Product Performance and Improvements - The recent data from V2 showed a 2x increase in analytical sensitivity and a 7% improvement in stage 1 performance for the Shield test [8][9] - The Shield test has high sensitivity for detecting advanced stages of cancer, with a focus on improving early-stage detection [9][10] Commercialization and Market Strategy - The company plans to expand its sales force to over 250 representatives by year-end, with productivity ramping up faster than expected [18] - Shield is currently covered by Medicare and the VA, with approximately 60 million people having access to it [20] Pricing and ASP (Average Selling Price) - The ASP for Guardant360 is currently between $3,000 and $3,100, with expectations to increase to $3,200 to $3,300 in the next couple of years [30][32] - The Medicare rate for Guardant360 increased to $5,000, contributing to higher ASPs [31] Market Penetration and Growth - The tissue market is about 50% penetrated, while the liquid biopsy market is around 30% [22][23] - Guardant Health anticipates over 27% volume growth for oncology, driven by innovation and the introduction of new applications [24][25] Future Outlook and Strategic Goals - The company aims to achieve cash flow break-even by the end of 2028, with significant strides expected in the oncology business excluding screening [58][60] - There is a strong belief in the potential for liquid biopsy to dominate the market, with expectations that tissue-free approaches will become more prevalent over the next decade [39] Biopharma Partnerships and International Growth - Partnerships with biopharma companies are evolving into strategic collaborations, enhancing the company's growth prospects [55] - The international market, particularly in China, is expected to be a significant driver of business growth [56] Monitoring and Testing Frequency - The company envisions a future where patients are tested multiple times per year, rather than just once per lifetime, particularly in the context of therapy selection [33][34] Gross Margin and Cost Management - The cost of goods sold for Reveal has decreased significantly, with a target of $400 per test by 2028, aiming for a gross margin of 60% [48][49] Conclusion - Guardant Health is positioned for substantial growth in the cancer diagnostics market, with innovative products, strategic partnerships, and a clear path towards profitability and market leadership in liquid biopsy technology [62]

Core Insights - Guardant Health, Inc. has announced a strategic partnership with PathGroup to expand the reach of its FDA-approved Shield blood test [1] Group 1 - The partnership will enable the Shield test to be available in over 250 hospitals and health systems [1] - More than 15,000 PathGroup-affiliated physicians across 25 states will be involved in the distribution of the Shield test [1]

Summary of Guardant Health (GH) FY Conference Call - August 13, 2025 Company Overview - **Company**: Guardant Health - **Industry**: Oncology diagnostics, specializing in liquid and tissue-based testing for cancer screening, therapy selection, and minimal residual disease (MRD) monitoring [2][3] Key Financial Highlights - **Clinical Volumes**: 30% year-over-year growth in oncology clinical volumes [3] - **Overall Revenue**: 31% year-over-year increase in total revenue [3] - **Average Selling Price (ASP)**: Tissue ASP increased from approximately $1,700 to $2,000, three years ahead of schedule [4][5] - **Gross Margin for Shield**: Achieved a gross margin of 48% in Q2, with a target cost per test of around $200 to potentially increase margins above 60% [15][17] Product Performance - **Tissue Testing**: Introduction of RNA features in tissue tests, contributing to ASP improvements and reimbursement from Medicare [6][7] - **Shield Product**: Expected to generate over $50 million in revenue with approximately 70,000 tests for the year; strong market pull and adoption exceeding internal expectations [11][12] - **Cost Reduction**: Significant reduction in cost per test for Shield from over $1,000 to below $500, with ongoing efforts to further decrease costs [14][15] Market Dynamics - **Colorectal Cancer (CRC) Screening**: Approximately 50 million people in the U.S. are unscreened; Guardant Health aims to convert a significant portion of this population through convenient blood tests [37][38] - **Market Share Potential**: The blood-based CRC screening market is substantial, with a doubling of screening rates observed when Shield tests are included in screening options [38][39] Future Developments - **Expansion Plans**: Plans to hire 250 sales representatives for Shield, increasing from a previous target of 200, with a long-term goal of 600-700 reps [19][20] - **Multi-Cancer Detection**: Shield is expected to evolve into a multi-cancer detection test, expanding beyond CRC to at least 10 different cancer types [24][36] - **Investor Day**: Upcoming Investor Day in late September 2025, anticipated to reveal new financial targets and updates on product performance [57][62] Competitive Landscape - **Market Position**: Guardant Health is positioned as a leader in the liquid biopsy market, with competitors showing lower sensitivity in their tests compared to Shield [34][35] - **Regulatory Engagement**: Positive discussions with ACS stakeholders regarding guideline inclusion for Shield, expected by the end of the year [40][46] Additional Insights - **AI Integration**: Guardant Health is leveraging AI in its applications, with a large dataset to enhance diagnostic capabilities [55][56] - **MRD Business Growth**: The Reveal MRD test is experiencing rapid growth, with significant demand in breast cancer monitoring [47][50] This summary encapsulates the key points discussed during the conference call, highlighting Guardant Health's strong performance, market opportunities, and future growth strategies.

Core Viewpoint - Gamehost Inc. reported positive financial results for the second quarter of 2025, with increases in operating revenue, EBITDA, and earnings per share, alongside a regular dividend declaration for shareholders [1][2][8]. Financial Performance - Operating revenue for the quarter increased by 2.3% to $20,771,100 compared to $20,303,500 in 2024 [2][6]. - EBITDA rose by 6.2% to $8,489,800 from $7,991,200 in the previous year [2][8]. - Earnings per share for the quarter were $0.25, up from $0.23 in 2024, reflecting a 12.6% increase [2][8]. Segment Performance - The hotel segment experienced double-digit growth, compensating for weaknesses in table holds during the quarter [2]. - Food and beverage sales also showed respectable growth, contributing positively to overall revenue [2]. Shareholder Returns - The company repurchased 198,100 common shares for a total of $2,194,200 and paid dividends amounting to $3,128,500 during the quarter [4]. - A monthly cash dividend of $0.05 per common share was declared for August 2025, equating to an annualized rate of $0.60 per share [8]. Market Context - Despite initial concerns regarding the impact of USA tariff proclamations, Alberta consumers continued to spend positively, favoring Canadian-made or local products [5]. - Federal and provincial governments are actively working to reduce interprovincial trade barriers, which may stimulate long-term investment decisions beneficial to Alberta [5].

Core Insights - Guardant Health reported Q2 2025 GAAP revenue of $232.1 million, surpassing analyst expectations of $211.5 million, and a Non-GAAP loss per share of ($0.44), better than the anticipated loss of ($0.73) per share, indicating strong growth momentum [1][2] Financial Performance - Revenue growth accelerated to 31% year over year, driven by increased customer adoption and higher reimbursement rates [5] - Non-GAAP gross margin improved to 66%, up from 60% a year earlier, reflecting better reimbursement and cost reductions [10] - Free cash flow improved to negative $65.9 million from negative $99.1 million in Q2 2024, attributed to timing differences in bonus payouts [11] Business Overview - Guardant Health specializes in blood- and tissue-based cancer tests for therapy selection, disease monitoring, and early screening, with flagship products including Guardant360, Guardant Reveal, and Shield [3] - The company focuses on innovation in oncology diagnostics, regulatory approvals, strategic partnerships, geographic expansion, and improving reimbursement landscapes [4] Segment Performance - Oncology segment revenue rose 22% to $158.7 million, with test volumes increasing by 30% year over year to nearly 64,000 [5] - Shield, the blood-based screening test for colorectal cancer, generated $14.8 million in revenue, with test volumes growing by 78% from the previous quarter [6] - The biopharma and data segment revenue reached $56.0 million, up 28% year over year, benefiting from increased research collaborations [7] Strategic Developments - Eleven new Smart Liquid Biopsy applications for Guardant360 were launched, enhancing clinical utility [8] - Shield received FDA Breakthrough Device Designation and was included in updated U.S. guidelines, supporting broader adoption [14] Outlook - Full-year 2025 revenue guidance was raised to $915–$925 million, reflecting strong momentum, with projected revenue growth of 24–25% year over year [15] - Gross margin targets increased to 63–64% for non-GAAP margin, with operating expenses expected to rise to $840–$850 million [16] - Free cash flow burn is projected at $225–$235 million, with expectations for the core business to reach free cash flow breakeven by Q4 2025 [16]

Core Insights - Guardant Health reported a revenue of $232.09 million for the quarter ended June 2025, reflecting a 31% increase year-over-year and surpassing the Zacks Consensus Estimate of $211.43 million by 9.77% [1] - The company’s EPS was -$0.44, an improvement from -$0.48 in the same quarter last year, with an EPS surprise of 15.38% against the consensus estimate of -$0.52 [1] Revenue Breakdown - Oncology revenue reached $158.69 million, exceeding the three-analyst average estimate of $153.38 million [4] - Licensing and other revenue was $2.57 million, surpassing the average estimate of $1.81 million from three analysts [4] - Screening revenue amounted to $14.81 million, significantly higher than the three-analyst average estimate of $8.31 million [4] - Biopharma and data revenue totaled $56.02 million, exceeding the average estimate of $48.06 million from three analysts [4] Stock Performance - Over the past month, shares of Guardant Health have declined by 14.6%, while the Zacks S&P 500 composite increased by 3.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Guardant Health (GH) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.48 per share a year ago. These figures are adjusted for non- recurring items. While Guardant Health has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earning ...